Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques L. Cadranel et al. · The Lancet Oncology · 2012

Cited by 956 works. doi:10.1016/s1470-2045(12)70087-6

Authors

References